NEW YORK (GenomeWeb News) – Proteome Sciences today said that revenues during the first half of 2012 rose 44 percent year over year.

For the period ended June 30, the Cobham, UK-based firm posted £892,827 ($1.4 million) in revenues, up from £618,982 for the first half of 2011. Grant services grew 53 percent year over year, Licenses/Sales/Services increased 38 percent, and TMT reagent sales rose 171 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.